ArticleJournal of molecular medicine (Berlin, Germany)2026
Loss of miR-146a induces cardiomyocyte proliferation after myocardial infarction through targeting Kctd15.
Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding miRNA‑146a: Mechanisms of action in cardiovascular diseases and endocrine metabolic disorders (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Accumulating evidence strongly confirms that microRNAs (miRNAs) play a pivotal role in the development and progression of cardiovascular diseases. Specifically, miR-146a has been demonstrated to be implicated in the pathogenesis of multiple cardiac diseases. Nevertheless, the role of miR-146a in ischemic heart disease and its underlying molecular mechanism remains unclear. The expression levels of miR-146a during different stages of cardiac development were detected by quantitative polymerase chain reaction (qPCR). Gain-of-function and loss-of-function assays were conducted to evaluate the impact of miR-146a on cardiomyocyte (CM) proliferation. A myocardial infarction (MI) model was established, and M-mode echocardiography and Masson's trichrome staining were used to further investigate the effects of miR-146a on cardiac function recovery post-MI. Then, bioinformatics approaches, including RNA-seq, were utilized to predict Kctd15 as a potential target gene of miR-146a. Finally, a dual luciferase reporter assay and rescue experiment were used to verify miR-146a interactions with Kctd15. First, we found that miR-146a expression decreased with age. Then, overexpression of miR-146a inhibited CM proliferation, while miR-146a inhibition promoted CM proliferation in vitro. Similarly, overexpression of miR-146a was impaired in cardiac function recovery post-MI, whereas miR-146a deficiency improved post-MI cardiac function. Further, bioinformatics analysis suggested that miR-146a might regulate CM proliferation by targeting Kctd15, which was confirmed by overexpression of Kctd15 blocking the effect of miR-146a on CM proliferation. The current study demonstrates that miR-146a regulates CM proliferation through the miR-146a/Kctd15 mRNA/Kctd15 protein pathway, which may provide a potential molecular target for preventing and treating myocardial injury. KEY MESSAGES: Acute myocardial infarction (AMI) accounts for about 7 million deaths per year worldwide; the existing treatment methods such as thrombolysis and percutaneous coronary interventions cannot achieve a good prognosis. This study demonstrates that miR-146a is a negative regulator of CM proliferation and exerts its function through Kctd15. Kctd15 was first proposed to be related to CM proliferation. The study provides new support for endogenous CM proliferation and treatment in other cardiovascular diseases.
Indexed as
Identifiers
41904351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.